Our experience in prolactinomas larger than 60 mm

Maiter, 2014, Therapy of endocrine disease: the challenges in managing giant prolactinomas, Eur J Endocrinol, 170, R213, 10.1530/EJE-14-0013 Berriel, 2016, Prolactinomas may have unusual presentations resulting from massive extrasellar tumor extension, Arq Neuropsiquiatr, 74, 544, 10.1590/0004-282X20160083 Shimon, 2016, Giant prolactinomas larger than 60mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas, Pituitary, 19, 429, 10.1007/s11102-016-0723-4 Gillam, 2006, Advances in the treatment of prolactinomas, Endocr Rev, 27, 485, 10.1210/er.2005-9998 Yu, 2005, Combined treatment of invasive giant prolactinomas, Pituitary, 8, 61, 10.1007/s11102-005-5087-0 Scarone, 2006, Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma Prompt response to medical treatment, J Neurooncol, 76, 51, 10.1007/s11060-005-2319-0 Olarescu, 2019, Aggressive and malignant prolactinomas, Neuroendocrinology, 109, 57, 10.1159/000497205 Espinosa, 2016, Giant prolactinomas: are they really different from ordinary macroprolactinomas?, Endocrine, 52, 652, 10.1007/s12020-015-0791-7 Iglesias, 2018, Giant prolactinoma in men: clinical features and therapeutic outcomes, Hormon Metab Res, 50, 791, 10.1055/a-0752-0741 Gürlek, 2007, What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics, Eur J Endocrinol, 156, 143, 10.1530/eje.1.02339 Yoo, 2018, Comparison of male and female prolactinoma patients requiring surgical intervention, J Neurol Surg B Skull Base, 79, 394, 10.1055/s-0037-1615748 Iglesias, 2004, Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy, Age Ageing, 33, 410, 10.1093/ageing/afh108 Brisman, 1993, Reversible dementia due to macroprolactinoma: case report, J Neurosurg, 79, 135, 10.3171/jns.1993.79.1.0135 Lam, 2012, Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature, Neurosurg Focus, 32, E2, 10.3171/2012.4.FOCUS1268 Singh, 2011, Bromocriptine or cabergoline-induced cerebrospinal fluid rhinorrhea: a life-threatening complication during management of prolactinoma, J Hum Reprod Sci, 4, 104, 10.4103/0974-1208.86096 Carija, 2012, Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review, CNS Neurol Disord Drug Targets, 11, 1012, 10.2174/1871527311211080011 Petignot, 2017